<DOC>
	<DOC>NCT01675011</DOC>
	<brief_summary>This is a randomized, prospective, multi-center study of 225 female subjects age 30-50 years with symptoms from uterine fibroids. All subjects will be followed for a total of thirty-six (36) months following uterine fibroid embolization.</brief_summary>
	<brief_title>Embozene Microspheres for Uterine Fibroid Embolization (UFE)</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Subject is able to provide informed consent and must sign the Institutional Review Board approved Informed Consent Form. Premenopausal women age 3050 years at time of enrollment Have been selected forUterine Fibroid Embolization (UFE) prior to entry to the study. Patient has a history of pelvic malignancy Patient has an abnormal Pap smear within 12 months of the planned Uterine Fibroid Embolization procedure Patient with coexisting condition that might explain abnormal bleeding (including endometrial hyperplasia and adenomyosis) or pelvic pain (including endometriosis and ovarian cysts). Is at substantial risk for the need of organ transplantation, such as renal insufficiency. Patient has evidence of current or recent pelvic inflammatory disease or uterine infection. Patient with a severe contrast allergy or renal insufficiency that would represent a contradiction to the administration of iodinebased contrast agents. Patients unable to comply with the followup requirements of the study.</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>